Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryAlaska Medicaid Aduhelm Prior Auth Coverage | Open…
    Ask Trek AI about this page
    CurrentAlaska MedicaidPolicy N/A

    Aduhelm (aducanumab-avwa) prior authorization - Coverage Criteria

    Customize your policy alerts

    Sign up for all Alaska Medicaid policy alerts

    Know when Alaska Medicaid releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document defines Alaska Medicaid prior authorization requirements, clinical criteria, and utilization limits for Aduhelm (aducanumab-avwa) infusions for treatment of Alzheimer's disease.

    Policy Summary
    PayerAlaska Medicaid
    PolicyAduhelm (aducanumab-avwa) prior authorization - Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionObtain prior authorization and document age ≥50, neurology prescriber/consult, confirmed beta‑amyloid by PET or CSF, baseline brain MRI within last year, and objective cognitive impairment.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥50minimum patient age for approval
    up to 3 moinitial authorization duration
    up to 6 moreauthorization duration
    10 mg/kgmaximum maintenance dose

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    MRI ≤1 yr
    baseline brain MRI

    Coverage Criteria for Aduhelm (aducanumab-avwa)

    Initial approval criteria

    Covered when ALL of the following are met

    Eligibility and prescriber: Patient is 50 years of age or older AND prescribed by or in consultation with a neurologist
    Diagnosis and biomarker confirmation: Patient has the diagnosis of Alzheimer's disease AND presence of beta-amyloid plaques verified by either a positron emission tomography (PET) scan or cerebrospinal fluid (CSF) testing
    Baseline MRI safety: Documented brain magnetic resonance imaging (MRI) within the last year showing no localized superficial siderosis, fewer than 10 brain microhemorrhages, and no brain hemorrhages > 1 cm in the past year<10 microhemorrhages
    Cognitive measures: Objective evidence of cognitive impairment at screening AND Clinical Dementia Rating (CDR) global score of 0.5 AND Mini-Mental State Exam (MMSE) >= 24MMSE >= 24
    Rule out other causes: Other known causes of dementia have been ruled out (e.g., vascular dementia, Parkinson's disease dementia)

    Reauthorization criteria

    Reauthorization covered when ALL of the following are met

    MRI monitoring: MRI obtained prior to the 7th and 12th doses showing no increase in size or number of ARIA-H
    Clinical benefit and safety: Documented evidence the patient is responding positively with slowed rate of cognitive decline and no adverse reactions

    Prior authorization for Aduhelm is not recommended for patients receiving systemic anticoagulation other than aspirin ≤81 mg. Patients who have had a brain hemorrhage, a diagnosed bleeding disorder, or significant cerebrovascular abnormalities within the prior 6 months are excluded from approval. Additionally, recent significant systemic illness or infection within the past 30 days or a history of unstable cardiac events (including unstable angina, myocardial infarction, advanced chronic heart failure, or clinically significant conduction abnormalities) within the past 1 year are grounds for denial.

    Use of Aduhelm is considered not approvable when the specified approval criteria are not met. Explicit denial triggers include failure to meet the approval criteria or the presence of any exclusionary condition listed (for example, use of disallowed anticoagulants or recent brain hemorrhage).

    Provider Requirements, Prior Authorization, and Denial Triggers

    Prior Authorization

    Prior authorization required; time-limited approvals and dosing

    Prior authorization is required. Initial approval is granted for up to 3 months. Reauthorization may be approved for up to 6 months only if MRI monitoring prior to doses 7 and 12 shows no increase in size or number of ARIA‑H and there is documented evidence of clinical benefit with no adverse reactions. Dosing follows the titration schedule up to a maximum of 10 mg/kg every 4 weeks from infusion 7 onward.

    • Initial Approval: up to 3 months
    • Reauthorization Approval: up to 6 months if MRI obtained prior to 7th and 12th doses shows no increase in ARIA‑H and patient demonstrates clinical benefit
    • Dose escalation per schedule with maximum 10 mg/kg every 4 weeks from infusion 7
    Step Therapy

    Step therapy not required

    No step therapy requirements are specified in this policy.

    Definitions and Key Terms

    Accelerated approval — definition and implications
    DefinitionAccelerated approval: regulatory pathway granting approval based on a surrogate endpoint (reduction in amyloid beta plaques) with requirement for confirmatory trials to verify clinical benefit.
    Basis for Aduhelm™ approvalApproved under accelerated approval based on observed reductions in amyloid beta plaques in treated patients.
    Implication for continued approvalContinued approval may be contingent upon verification of clinical benefit in confirmatory trial(s).
    Intended treatment populationInitiation limited to patients with mild cognitive impairment or mild dementia — the population studied in clinical trials.
    LimitationsNo safety or effectiveness data to support initiating treatment at earlier or later stages than those studied.

    Background

    Aduhelm (aducanumab-avwa) is an amyloid beta-directed monoclonal antibody indicated for treatment of Alzheimer’s disease under an accelerated approval pathway. The accelerated approval is based on reduction of amyloid beta plaques as a surrogate endpoint; because safety and clinical benefit must be confirmed in ongoing studies, careful patient selection and monitoring are required, and use is subject to prior authorization and the policy’s specific exclusion criteria.

    Policy Summary
    PayerAlaska Medicaid
    PolicyAduhelm (aducanumab-avwa) prior authorization - Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionObtain prior authorization and document age ≥50, neurology prescriber/consult, confirmed beta‑amyloid by PET or CSF, baseline brain MRI within last year, and objective cognitive impairment.
    SourceLink
    On This Page
    Coverage Criteria for Aduhelm (aducanumab-avwa)Provider Requirements, Prior Authorization, and Denial TriggersDefinitions and Key TermsBackground
    Documentation Required

    Required documentation for initial request and reauthorization

    Providers must supply documentation at initial request and for reauthorization that demonstrates the approval criteria and monitoring requirements are met.

    • Patient age ≥ 50
    • Prescribed by or in consultation with a neurologist
    • Diagnosis of Alzheimer’s disease and presence of beta‑amyloid plaques verified by PET or CSF
    • Baseline brain MRI within the last year showing no localized superficial siderosis, <10 brain microhemorrhages, and no brain hemorrhage >1 cm in the past year
    • Objective evidence of cognitive impairment at screening, CDR global score 0.5, and MMSE ≥ 24
    • For reauthorization: MRIs obtained prior to the 7th and 12th doses showing no increase in size or number of ARIA‑H, plus documented clinical benefit and absence of adverse reactions
    Denial Risk

    Triggers for denial and high-risk exclusions

    Denial will be issued when approval criteria are not met or when safety exclusions apply.

    • Failure to meet the stated approval criteria
    • Use of any blood thinners other than aspirin 81 mg or less
    • Brain hemorrhage, bleeding disorder, or cerebrovascular abnormalities within the last 6 months
    • Significant systemic illness or infection in the past 30 days
    • History of unstable angina, myocardial infarction, advanced chronic heart failure, or clinically significant conduction abnormalities within 1 year prior to screening
    ARIA — Amyloid Related Imaging Abnormalities and monitoring requirements
    DefinitionARIA (Amyloid Related Imaging Abnormalities) includes ARIA‑E (edema) and ARIA‑H (microhemorrhage and superficial siderosis).
    Timing of highest riskEnhanced clinical vigilance is recommended during the first 8 doses, particularly during dose titration.
    Monitoring actionIf symptoms suggestive of ARIA occur, perform clinical evaluation and obtain MRI testing if indicated.
    Common related adverse reactionsMost common adverse reactions include ARIA‑Edema, ARIA‑H microhemorrhage, ARIA‑H superficial siderosis, headache, and falls.